Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

New treatment for fibromyalgia

09.09.2004


Study demonstrates effectiveness of the antidepressant duloxetine for improving symptoms and relieving pain



Fibromyalgia is a chronic, incapacitating musculoskeletal disorder. Nearly six times more common in women than in men, fibromyalgia is marked by widespread body pain and muscle tenderness, often accompanied by headaches, sleep disturbances, and fatigue. While its cause remains a mystery, fibromyalgia has been linked to abnormalities in the brain’s neurotransmitters, serotonin and norepinephrine--chemicals key to mood and widely recognized for their role in depression. Not all patients with fibromyalgia, however, have depression or respond to antidepressants. Treatment studies of the other types of antidepressant drugs, including selective serotonin uptake inhibitors and tricyclic agents, have had mixed results.

A new and different antidepressant, duloxetine, works by inhibiting the reuptake of both serotonin and norepinephrine. In a recent clinical trial conducted for the treatment of fibromyalgia--one of the largest ever--duloxetine was shown to reduce pain and improve a range of disease symptoms, significantly and safely. The results, published in the September 2004 issue of Arthritis & Rheumatism, offer the promise of relief for women with fibromyalgia.


"Our results suggest that duloxetine improves pain and tenderness, the hallmark characteristics of fibromyalgia," states Lesley M. Arnold, M.D., who coordinated the research at 18 centers, including the University of Cincinnati College of Medicine, Indiana University Medical School, and Harvard Medical School. "The effect of duloxetine on the reduction of pain," Dr. Arnold further notes, "appears to be independent of its effect on mood."

To test duloxetine’s effectiveness on the range of symptoms, researchers recruited 207 patients, all meeting the American College of Rheumatology criteria for fibromyalgia. Like the majority of those with this disease, the majority of the participants--89 percent--were women. 87 percent of the subjects were Caucasian and the mean age was 49. Just over a third of the patients--38 percent--had been diagnosed with depression. On a random basis, the patients were prescribed one of two treatments for a course of 12 weeks. About half, 104 individuals, received 60 milligrams of duloxetine twice a day. The remaining 103 patients were given a placebo. Both groups were evaluated and scored, using the Fibromyalgia Impact Questionnaire and other standard measures, for improvements in their condition.

In various measures of disease--from pervasive pain to tiredness to tenderness--the female fibromyalgia patients treated with duloxetine improved significantly over those treated with a placebo. One of the most dramatic changes was in the reduction of the number of tender points--places on the body where it hurts to touch--and the increase of pressure pain threshold. Women with or without depression receiving duloxetine benefited emotionally and physically, reporting improvements in general mood, ability to function, and overall enjoyment of life.

For the study’s 23 men, however, duloxetine did little to change their condition. Although researchers reported some evidence of improvement in tender point measures among duloxetine-treated men over their placebo-treated counterparts, it was not statistically significant. "The reasons for the sex differences in response are unclear," Dr. Arnold observes. "Because the male subgroup was small, reflecting the much higher prevalence of fibromyalgia in women, the results of the study may not be generalizable to all men with fibromyalgia. There may also be sex differences in fibromyalgia that affect treatment response."

As Dr. Arnold notes, further research is needed on larger samples of not only men but also other groups with fibromyalgia to evaluate duloxetine’s effectiveness.

Amy Molnar | EurekAlert!
Further information:
http://www.wiley.com

More articles from Health and Medicine:

nachricht Cholesterol-lowering drugs may fight infectious disease
22.08.2017 | Duke University

nachricht Once invincible superbug squashed by 'superteam' of antibiotics
22.08.2017 | University at Buffalo

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Fizzy soda water could be key to clean manufacture of flat wonder material: Graphene

Whether you call it effervescent, fizzy, or sparkling, carbonated water is making a comeback as a beverage. Aside from quenching thirst, researchers at the University of Illinois at Urbana-Champaign have discovered a new use for these "bubbly" concoctions that will have major impact on the manufacturer of the world's thinnest, flattest, and one most useful materials -- graphene.

As graphene's popularity grows as an advanced "wonder" material, the speed and quality at which it can be manufactured will be paramount. With that in mind,...

Im Focus: Exotic quantum states made from light: Physicists create optical “wells” for a super-photon

Physicists at the University of Bonn have managed to create optical hollows and more complex patterns into which the light of a Bose-Einstein condensate flows. The creation of such highly low-loss structures for light is a prerequisite for complex light circuits, such as for quantum information processing for a new generation of computers. The researchers are now presenting their results in the journal Nature Photonics.

Light particles (photons) occur as tiny, indivisible portions. Many thousands of these light portions can be merged to form a single super-photon if they are...

Im Focus: Circular RNA linked to brain function

For the first time, scientists have shown that circular RNA is linked to brain function. When a RNA molecule called Cdr1as was deleted from the genome of mice, the animals had problems filtering out unnecessary information – like patients suffering from neuropsychiatric disorders.

While hundreds of circular RNAs (circRNAs) are abundant in mammalian brains, one big question has remained unanswered: What are they actually good for? In the...

Im Focus: RAVAN CubeSat measures Earth's outgoing energy

An experimental small satellite has successfully collected and delivered data on a key measurement for predicting changes in Earth's climate.

The Radiometer Assessment using Vertically Aligned Nanotubes (RAVAN) CubeSat was launched into low-Earth orbit on Nov. 11, 2016, in order to test new...

Im Focus: Scientists shine new light on the “other high temperature superconductor”

A study led by scientists of the Max Planck Institute for the Structure and Dynamics of Matter (MPSD) at the Center for Free-Electron Laser Science in Hamburg presents evidence of the coexistence of superconductivity and “charge-density-waves” in compounds of the poorly-studied family of bismuthates. This observation opens up new perspectives for a deeper understanding of the phenomenon of high-temperature superconductivity, a topic which is at the core of condensed matter research since more than 30 years. The paper by Nicoletti et al has been published in the PNAS.

Since the beginning of the 20th century, superconductivity had been observed in some metals at temperatures only a few degrees above the absolute zero (minus...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Call for Papers – ICNFT 2018, 5th International Conference on New Forming Technology

16.08.2017 | Event News

Sustainability is the business model of tomorrow

04.08.2017 | Event News

Clash of Realities 2017: Registration now open. International Conference at TH Köln

26.07.2017 | Event News

 
Latest News

Researchers devise microreactor to study formation of methane hydrate

23.08.2017 | Materials Sciences

ShAPEing the future of magnesium car parts

23.08.2017 | Automotive Engineering

New insights into the world of trypanosomes

23.08.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>